Aurinia Pharmaceuticals Inc logo

Aurinia Pharmaceuticals Inc

NAS:AUPH (Canada)  
$ 7.77 -0.11 (-1.4%) 11:08 PM EST
P/E:
At Loss
P/B:
2.84
Market Cap:
$ 1.11B
Enterprise V:
$ 864.17M
Volume:
2.20M
Avg Vol (2M):
2.09M
Also Trade In:
Volume:
2.20M
Market Cap $:
1.11B
PE Ratio:
At Loss
Avg Vol (2M):
2.09M
Enterprise Value $:
864.17M
PB Ratio:
2.84

Business Description

Description
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States.
Name Current Vs Industry Vs History
Cash-To-Debt 3.47
Equity-to-Asset 0.72
Debt-to-Equity 0.26
Debt-to-EBITDA -1.32
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.61
Distress
Grey
Safe
Beneish M-Score -1.88
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 17.85
9-Day RSI 24.73
14-Day RSI 30.13
6-1 Month Momentum % -18.72
12-1 Month Momentum % 22.95

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 6.75
Quick Ratio 6.21
Cash Ratio 5.69
Days Inventory 1774.72
Days Sales Outstanding 51.05
Days Payable 243.1

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -8.4
Shareholder Yield % -1.64

Financials (Next Earnings Date:2023-11-03 Est.)

AUPH's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:AUPH

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

Aurinia Pharmaceuticals Inc Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 160.117
EPS (TTM) ($) -0.5
Beta 1.43
Volatility % 127.7
14-Day RSI 30.13
14-Day ATR ($) 0.402367
20-Day SMA ($) 8.919
12-1 Month Momentum % 22.95
52-Week Range ($) 4.07 - 12.43
Shares Outstanding (Mil) 143.42

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Aurinia Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Aurinia Pharmaceuticals Inc Stock Events

Event Date Price($)
No Event Data

Aurinia Pharmaceuticals Inc Frequently Asked Questions

What is Aurinia Pharmaceuticals Inc(AUPH)'s stock price today?
The current price of AUPH is $7.77. The 52 week high of AUPH is $12.43 and 52 week low is $4.07.
When is next earnings date of Aurinia Pharmaceuticals Inc(AUPH)?
The next earnings date of Aurinia Pharmaceuticals Inc(AUPH) is 2023-11-03 Est..
Does Aurinia Pharmaceuticals Inc(AUPH) pay dividends? If so, how much?
Aurinia Pharmaceuticals Inc(AUPH) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1